Olanzapine for young PEople with aNorexia nervosa: An open-label feasibility study to test recruitment, treatment acceptance, adherence, safety, outcome measures and patients' experience to prepare for a randomised placebo-controlled trial (OPEN)

奥氮平治疗患有神经性厌食症的年轻人：一项开放标签可行性研究，旨在测试招募、治疗接受度、依从性、安全性、结果测量和患者体验，为随机安慰剂对照试验 (OPEN) 做准备

• 批准号: nhmrc : 2005717
• 金额: $ 19.08万
• 依托单位国家: 澳大利亚
• 项目类别: International Collaborations
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/olanzapine-young-people-trial-open/1779579
• 关键词: Olanzapine; young; PEople; aNorexia; nervosa

Olanzapine seems to be a helpful and safe medication in anorexia nervosa (AN), but it is not approved for AN. We will perform a preliminary study with 70 patients with AN (15 in Australia and 50 in the UK, age: 12-24 years) who can safely take olanzapine and have not gained sufficient weight or experienced improvement in their AN symptoms under specialist care. We will the acceptability and feasibility of olanzapine in AN. Patients will be examined after 8 and 16 weeks, 6 months and 12 months.

奥氮平似乎是治疗神经性厌食症 (AN) 的一种有效且安全的药物，但尚未批准用于治疗 AN。我们将对 70 名 AN 患者（澳大利亚 15 名，英国 50 名，年龄：12-24 岁）进行一项初步研究，这些患者可以安全服用奥氮平，但在专科护理下体重没有增加足够或 AN 症状没有改善。我们将了解奥氮平在 AN 中的可接受性和可行性。患者将在 8 周、16 周、6 个月和 12 个月后接受检查。